Clinical trial / 2013
Vitamin D3 supplementation up to 5,000 IU/d significantly increased serum 25(OH)D3 and reduced disease activity scores in Crohn's disease patients.
A pilot study evaluated 18 patients with mild-to-moderate Crohn's disease receiving escalating doses of oral vitamin D3 (from 1,000 IU/d up to 5,000 IU/d) for 24 weeks to reach serum levels above 40 ng/ml. Fourteen of the 18 patients required the maximal dose of 5,000 IU/d. Supplementation significantly increased serum 25(OH)D3 levels from 16±10 ng/ml to 45±19 ng/ml (P<0.0001) and reduced unadjusted mean CDAI scores by 112±81 points from 230±74 to 118±66 (P<0.0001). Quality-of-life scores also significantly improved (P=0.0004), while no significant changes in cytokines or other laboratory measures were observed.
- Study type
- Pilot intervention study
- Who was studied
- 18 patients with mild-to-moderate Crohn's disease (CDAI scores 150-400)
- What was measured
- Serum 25(OH)D3 levels, CDAI scores, quality of life, bone mineral density, and laboratory measures
THE PAPER
Therapeutic effect of vitamin d supplementation in a pilot study of Crohn's patients.
Yang L, Weaver V, Smith JP, Bingaman S, Hartman TJ, Cantorna MT. Clin Transl Gastroenterol, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.